|
**Overview**: Growth Hormone Suppression Panel**Introduction**: The Growth Hormone Suppression Panel is a diagnostic tool designed to assess growth hormone suppression using serum samples. In India, GH suppression testing (oral glucose tolerance test) is essential for diagnosing acromegaly/gigantism (~3-4 cases per million annually), where failure to suppress GH (<1 ng/mL) after glucose load indicates autonomous secretion from pituitary adenoma. High morbidity from under-testing in rural/low-SES patients with enlarged extremities, coarse features, or excessive growth, limited endocrine labs, delayed somatostatin analogs/surgery leading to diabetes, hypertension, or cardiomyopathy. Per endocrinology practices aligned with ICMR and Endocrine Society of India guidelines, the test employs immunoassay for basal GH and post-glucose GH levels (multiple time points) over 1-2 days with high accuracy, valuable for confirming acromegaly in patients with clinical suspicion. This diagnostic falls under hormonal screening and targets adults/children with acromegaly features or high IGF-1, addressing accurate detection to guide medical/surgical therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise GH axis evaluation and reducing acromegaly complications. Its serum-based approach ensures reliable dynamic suppression assessment.**Other Names**: GH Supp Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology, compliant with 2025 standards.**Historical Milestone**: GH suppression standard; in India, used in pituitary clinics.**Purpose**: The test assesses 3 parameters including basal GH to guide growth hormone suppression evaluation, confirm autonomous secretion, inform therapy.**Test Parameters**: 1. Basal GH, 2â€"3. Post-Glucose GH Levels (2 Time Points).**Pretest Condition**: Fasting 10-12 hours required; patients should have suspected acromegaly.**Specimen**: 3 mL serum in 1 SST (multiple timed draws), transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on acral enlargement, headache, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of glucose load (hypoglycemia in rare cases), benefits of confirming acromegaly, and minimal discomfort from multiple venipunctures.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret GH suppression within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols. Glucose load is administered under supervision.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or glucose intolerance can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Failure to suppress GH confirms acromegaly, necessitating specialist input. Normal suppression may require follow-up.**Specialist Consultation**: Endocrinologists should be consulted for management.**Additional Supporting Tests**: IGF-1, pituitary MRI for confirmation.**Test Limitations**: Requires glucose tolerance; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Pituitary Studies India 2023. |
